Ventyx Biosciences Engages with Healthcare Leaders
SAN DIEGO, Ventyx Biosciences, Inc. (NASDAQ: VTYX), a clinical-stage biopharmaceutical company renowned for developing groundbreaking therapies, is set to participate in the Piper Sandler Annual Healthcare Conference.
Exciting Conference Participation
This year's conference will feature a dedicated fireside chat with Ventyx executives, presenting an invaluable opportunity to discuss the company's innovations in treatment for inflammation-mediated cardiovascular and neurodegenerative diseases.
Live Event Details
The fireside chat is scheduled for an afternoon session, allowing attendees to gain insights into Ventyx's latest research and development efforts. This session promises to shed light on the future prospects and ongoing initiatives within the company.
Innovative Therapeutics Portfolio
Ventyx Biosciences specializes in creating innovative oral therapies. The company excels in medicinal chemistry, structural biology, and immunology, focusing on oral small molecule therapeutics for significant unmet medical needs.
NLRP3 Inhibitors: Leading the Charge
A highlight of Ventyx's offerings is their portfolio of NLRP3 inhibitors. This includes VTX2735, which is currently in Phase 2 development specifically targeting recurrent pericarditis. Additionally, VTX3232 is a CNS-penetrant NLRP3 inhibitor that has recently completed studies addressing obesity-related cardiovascular risks and recently investigated Parkinson's Disease.
Advancements in Inflammatory Bowel Disease Treatments
The company also has promising programs for inflammatory bowel disease. Among these are tamuzimod (VTX002), an S1P1R modulator, and VTX958, a TYK2 inhibitor, both of which are now in Phase 2 trials.
Access to Information
Investors and interested parties can follow the developments from the conference via a live webcast hosted in the Investors and News section of Ventyx's official website. This will include comprehensive insights and updates post-event, ensuring that stakeholders remain informed.
Your Connection to Ventyx Biosciences
For those wanting to delve deeper into the groundbreaking work being done at Ventyx, their website serves as an excellent resource. Visitors can explore information related to their product pipeline, research initiatives, and corporate updates.
Investor Relations Contact
Alex Schwartz, Vice President of Investor Relations and FP&A, leads Ventyx's communication with investors and can be reached for inquiries regarding the company's performance and future outlook.
Frequently Asked Questions
What is Ventyx Biosciences known for?
Ventyx Biosciences is a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for cardiovascular and neurodegenerative diseases.
When will Ventyx participate in the Piper Sandler Conference?
Ventyx will participate in the Piper Sandler Annual Healthcare Conference with a fireside chat scheduled on December 3.
What therapies are being developed by Ventyx?
Ventyx is developing oral therapies for inflammation-mediated diseases, with a portfolio that includes NLRP3 inhibitors and compounds for inflammatory bowel disease.
How can I follow the conference?
A live webcast of the event can be accessed through Ventyx's official website in the Investors and News section.
Who should I contact for more information?
For details regarding investor relations, you can reach out to Alex Schwartz, Vice President of Investor Relations and FP&A at Ventyx Biosciences.